Business
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately USD 1.4bn on a fully diluted basis Basel, September 9, 2
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8.Z9AtxDZu.YBzmEDXcFqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jueXpDUxpWmMEybgAo8Oaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":1200,"height":675}},"lazy":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Pacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment ","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Offer price of USD 48 per share valuing the company at approximately USD 1.4bn on a fully diluted basis","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":477,"olType":false},{"type":"text","content":"Basel, September 9, 2025 – Novartis today announced that it has entered into an agreement to acquire Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a New York-based, publicly traded clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease. Pacibekitug complements Novartis’ cardiovascular strategy by targeting IL-6, a key upstream cytokine that promotes systemic inflammation, thus addressing a critical unmet need. With Phase 21 trials already well advanced, Novartis will acquire a Phase 3 ready asset which will complement its existing cardiovascular disease portfolio.","length":680,"tagName":"p"},{"type":"text","content":"“With no widely adopted anti-inflammatory t...